TY - JOUR
T1 - Auditory and Visual Mismatch Negativity in Psychiatric Disorders
T2 - A Review
AU - Maekawa, Toshihiko
AU - Hirano, Shogo
AU - Onitsuka, Toshiaki
PY - 2012/5
Y1 - 2012/5
N2 - Event-related potentials (ERPs) provide an objective index of neurocognitive abnormality or dysfunction in neuropsychiatric disorders. Auditory mismatch negativity (aMMN), which was discovered in the 1980s, is one unique type of ERP. Several lines of evidence suggest that it reflects auditory preattentive (automatic) information processing and the function of glutamatergic N-methyl-D-aspartate receptors. Many studies also have suggested that aMMN is a promising biomarker for some psychiatric disorders such as schizophrenia. Prospective studies combining analyses of several biomarkers, including aMMN, in schizophrenia patients from the prodromal period, are underway. Meanwhile, the existence of a visual counterpart of aMMN (vMMN) has been disputed, and a genuine vMMN was only confirmed in the last decade. Thus, there have been a relatively small number of vMMN studies compared with studies of aMMN, and the mechanism underlying vMMN is still unclear. However, it is well known that abnormal auditory and visual sensory information processing is present in psychiatric disorders, and vMMN is an important component of ERPs studied in psychiatric patients. The aim of this review is to provide an overview of recent aMMN and vMMN findings in several psychiatric disorders, including schizophrenia, major depression, Alzheimer's disease, and developmental disorders. In doing so, we highlight their potential use as biomarkers of psychiatric disorders.
AB - Event-related potentials (ERPs) provide an objective index of neurocognitive abnormality or dysfunction in neuropsychiatric disorders. Auditory mismatch negativity (aMMN), which was discovered in the 1980s, is one unique type of ERP. Several lines of evidence suggest that it reflects auditory preattentive (automatic) information processing and the function of glutamatergic N-methyl-D-aspartate receptors. Many studies also have suggested that aMMN is a promising biomarker for some psychiatric disorders such as schizophrenia. Prospective studies combining analyses of several biomarkers, including aMMN, in schizophrenia patients from the prodromal period, are underway. Meanwhile, the existence of a visual counterpart of aMMN (vMMN) has been disputed, and a genuine vMMN was only confirmed in the last decade. Thus, there have been a relatively small number of vMMN studies compared with studies of aMMN, and the mechanism underlying vMMN is still unclear. However, it is well known that abnormal auditory and visual sensory information processing is present in psychiatric disorders, and vMMN is an important component of ERPs studied in psychiatric patients. The aim of this review is to provide an overview of recent aMMN and vMMN findings in several psychiatric disorders, including schizophrenia, major depression, Alzheimer's disease, and developmental disorders. In doing so, we highlight their potential use as biomarkers of psychiatric disorders.
UR - http://www.scopus.com/inward/record.url?scp=84860283980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860283980&partnerID=8YFLogxK
U2 - 10.2174/1573400511208020097
DO - 10.2174/1573400511208020097
M3 - Article
AN - SCOPUS:84860283980
SN - 2666-0822
VL - 8
SP - 97
EP - 105
JO - Current Psychiatry Research and Reviews
JF - Current Psychiatry Research and Reviews
IS - 2
ER -